KRTX News and Press, Karuna Therapeutics Inc. From 05/22/23

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that data from the EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials evaluating Ka...

2023-05-06 02:55:16 ET Karuna Therapeutics, Inc. (KRTX) Q1 2023 Earnings Conference Call May 04, 2023, 08:00 AM ET Company Participants Alexis Smith - Senior Director of Investor Relations Bill Meury - President and Chief Executive Officer Troy Ignelzi - Chief Fi...

2023-05-04 06:32:32 ET Karuna Therapeutics press release ( NASDAQ: KRTX ): Q1 GAAP EPS of -$2.80 misses by $0.01 . Revenue of $0.65M. Announced positive topline data from the Phase 3 EMERGENT-3 trial of KarXT in schizophrenia in the first quarter of 2023 On tra...

Announced positive topline data from the Phase 3 EMERGENT-3 trial of KarXT in schizophrenia in the first quarter of 2023 On track to submit New Drug Application (NDA) for KarXT in schizophrenia with the U.S. FDA in the third quarter of 2023, with a launch in the second half of 2024, if ap...

2023-05-03 13:50:04 ET Karuna Therapeutics ( NASDAQ: KRTX ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is -$2.70 (-38.5% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS es...

2023-04-29 08:25:00 ET 89bio (NASDAQ: ETNB) , Karuna Therapeutics (NASDAQ: KRTX) , and Morphic Therapeutics (NASDAQ: MORF) are clinical-stage biotech companies that make attractive buyout targets. Their financial positions may not be great, as they all have littl...

2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...

2023-04-22 00:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A crisis-driven rotati...

Conference call and webcast to take place on Thursday, May 4, 2023 at 8:00 a.m. ET Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, t...

2023-04-19 09:01:34 ET With several large M&A deals involving biotechs being acquired so far in 2023, RBC Capital Markets says such activity could be on the rise ahead. Given recent M&A activity, we "remind investors that there remains M&A appetite among large pharmas,...